Richard D Kennedy (Richard Kennedy)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Early Breast Cancer

Tyrosine Kinase

Endoplasmic Reticulum

Dna Damage Response

Top Venues

Journal of oncology

Molecular cancer research : MCR

JCO precision oncology

NPJ breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Daryl Griffin, Robbie Carson, Deborah Y Moss, Tamas Sessler, Deborah P Lavin, Vijay K Tiwari, Shivaali Karelia, Richard D Kennedy, Kienan I Savage, Simon S McDade, Adam Carie, Jim Pankovich, Mark Bazett, Sandra Van Schaeybroeck
Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. Molecular cancer research : MCR (2024)
Daryl Griffin, Robbie Carson, Deborah Y Moss, Tamas Sessler, Deborah P Lavin, Vijay K Tiwari, Shivaali Karelia, Richard D Kennedy, Kienan I Savage, Simon S McDade, Adam Carie, Jim Pankovich, Mark Bazett, Sandra Van Schaeybroeck
Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. Molecular cancer research : MCR (2024)
Shane R Stecklein, William E Barlow, Lajos Pusztai, Kirsten Timms, Richard D Kennedy, Gemma E Logan, Robert S Seitz, Sunil S Badve, Yesim Gökmen-Polar, Peggy Porter, Hannah Linden, Debasish Tripathy, Gabriel N Hortobagyi, Andrew K Godwin, Alastair Thompson, Daniel F Hayes, Priyanka Sharma
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO precision oncology 7 (2023)
Holly Tovey, Orsolya Sipos, Joel S Parker, Katherine A Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Suzanne Kilburn, Roberto Salgado, Sherene Loi, Richard D Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E Pinder, Judith M Bliss, Charles M Perou, Syed Haider, Anita Grigoriadis, Andrew N J Tutt, Maggie Chon U Cheang
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Eileen E Parkes, Matthew P Humphries, Elaine Gilmore, Fatima Abdullahi Sidi, Victoria Bingham, Su M Phyu, Stephanie Craig, Catherine Graham, Joseph Miller, Daryl Griffin, Manuel Salto-Tellez, Stephen F Madden, Richard D Kennedy, Samuel F Bakhoum, Stephen McQuaid, Niamh E Buckley
The clinical and molecular significance associated with STING signaling in breast cancer. NPJ breast cancer 7 (1) (2021)
Eileen E Parkes, Kienan I Savage, Tong Lioe, Clinton Boyd, Sophia Halliday, Steven M Walker, Keith Lowry, Laura Knight, Niamh E Buckley, Andrena Grogan, Gemma E Logan, Alison Clayton, Jane Hurwitz, Stephen J Kirk, Jiamei Xu, Fatima Abdullahi Sidi, Matthew P Humphries, Victoria Bingham, null null, Jaqueline A James, Colin R James, D Paul Harkin, Richard D Kennedy, Stuart A McIntosh
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. British journal of cancer (2021)
Richard D A Wilkinson, Roberta E Burden, Sara H McDowell, Darragh G McArt, Stephen McQuaid, Victoria Bingham, Rich Williams, Órla T Cox, Rosemary O'Connor, Nuala McCabe, Richard D Kennedy, Niamh E Buckley, Christopher J Scott
A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. Journal of oncology 2019 (2019)
Elaine Gilmore, Nuala McCabe, Richard D Kennedy, Eileen E Parkes
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of oncology 2019 (2019)
Matthew Phillip Humphries, Seán O Hynes, Victoria Bingham, Delphine Cougot, Jacqueline A James, Farah Patel-Socha, Eileen E Parkes, Jaine K Blayney, Michael A O'Rorke, Gareth W Irwin, Darragh G McArt, Richard D Kennedy, Paul B Mullan, Stephen McQuaid, Manuel Salto Tellez, Niamh E Buckley
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of oncology 2018 (2018)